INTRODUCTION

Principles
T he 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines continue to adhere to some fundamental principles that inspired the 2003 and 2007 guidelines, namely to base recommendations on properly conducted studies identified from an extensive review of the literature; to consider, as the highest priority, data from randomized, controlled trials and their meta-analyses, but not to disregard the results of observational and other studies of appropriate scientific calibre; and to grade the level of scientific evidence and the strength of recommendations in order to more effectively alert physicians on recommendations that are based on the opinions of the experts rather than on evidence (Tables 1  and 2 ). When appropriately recognized, this can avoid guidelines being perceived as prescriptive and favour the performance of studies wherein opinion prevails and evidence is lacking.
This shortened version of the ESH/ESC guidelines is for the practicing physician who often requires simplified information. However, whenever the physicians would like to know the source of the data upon which the recommendations are based, they are encouraged to consult the extensive version of the ESH/ESC guidelines wherein adequate references are given. These guidelines, however, do not override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient.
New aspects
Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ from the 2007 ones in several points:
1. Re-emphasis on integration of blood pressure (BP), cardiovascular risk factors, asymptomatic organ damage and clinical complications for total cardiovascular risk assessment. 2. Update of the prognostic significance of out-of-office BP (both ambulatory and home BP), white-coat hypertension and masked hypertension. 3. Initiation of antihypertensive drug treatment only in patients with SBP or DBP values at least 140 or 90 mmHg, independent of level of total cardiovascular risk.
4. Unified target SBP (<140 mmHg) in both higher and lower cardiovascular risk patients. 5. Revised recommendations on treatment of hypertension in young people and in the elderly. 6. Liberal approach to initial monotherapy, without any all-ranking purpose scheme. 7. Revised therapeutic algorithm for achieving target BP. 8. Revised attention to resistant hypertension.
DEFINITIONS AND CLASSIFICATIONS
The continuous relationship between BP and cardiovascular and renal events make the distinction between normotension and hypertension difficult. In practice, however, cut-off BP values are universally used to facilitate the decision about treatment (Table 3) .
In order to help prognosis, total cardiovascular risk should be stratified in different categories (low, moderate, high and very high risk referred to the 10-year risk of cardiovascular mortality), based on BP category, cardiovascular risk factors, asymptomatic organ damage and presence of diabetes, and symptomatic cardiovascular disease or chronic kidney disease (CKD), as summarized in Fig. 1 .
DIAGNOSTIC EVALUATION
The initial evaluation of a patient with hypertension should confirm the diagnosis of hypertension; detect causes of secondary hypertension; and assess cardiovascular risk, organ damage and concomitant clinical conditions. This calls for BP measurement, medical history including family history, physical examination, laboratory investigation and further diagnostic tests. Some of the investigations are needed in all patients; others only in specific patient groups.
3.1 Blood pressure measurement 3.1.1 Office and out-of-office blood pressure Although conventional office BP measurement currently remains the 'gold standard' for screening, diagnosis and management of hypertension, it is generally accepted that out-of-office BP provides important adjunct information. Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.
Class III Is not recommended
At present, BP can no longer be estimated using a mercury manometer in many -although not all -European countries. Auscultatory or oscillometric semiautomatic sphygmomanometers are used instead, but these devices should be validated according to standardized protocols and their accuracy checked periodically. Table 4 gives instructions for correct office BP measurements, and Table 5 provides clinical indications for out-of-office BP measurement, namely measurements at home or over the 24 h.
Office BP is usually higher than ambulatory and home BP and the difference increases as office BP increases. Cut-off values for the definition of hypertension by home and ambulatory BP are reported in Table 6 .
White-coat and masked hypertension
The term 'white-coat' or 'isolated office' hypertension refers to a condition in which BP is elevated in the office at repeated visits and normal out of the office either on ambulatory blood pressure monitoring or on home blood pressure monitoring. Conversely, BP may be normal in the office and abnormally high out of the medical environment, which is termed 'masked' or 'isolated ambulatory' hypertension. Cut-off values to be used are those in Table 6 .
Central blood pressure
Owing to the variable superposition of incoming and reflected pressure waves along the arterial tree, aortic BP (central BP) may be different from brachial BP. Central BP can be estimated indirectly by various methods. The current guidelines consider that, despite the growing interest in these methods, more investigation is needed before recommending the routine measurement of central BP for clinical use.
Medical history
The information to be obtained at the time of the first diagnosis of hypertension is indicated in Table 7 .
Physical examination
Physical examination aims to establish or verify the diagnosis of hypertension, establish current BP, screen for secondary causes of hypertension and refine global cardiovascular risk. Procedures for BP measurement are indicated in Tables 4 and 5 . Other information to be obtained by physical examination is in Table 8 . Consensus of opinion of the experts and/or small studies, retrospective studies, registries Level of evidence C FIGURE 1 Stratification of total cardiovascular risk in categories of low, moderate, high and very high risk according to SBP and DBP and presence of risk factors (RFs), asymptomatic organ damage (OD), diabetes, chronic kidney disease (CKD) stage or symptomatic cardiovascular disease (CVD). Individuals with a high normal office but a raised out-of-office BP (masked hypertension) have a cardiovascular risk in the hypertension range. Individuals with a high office BP but normal out-of-office BP (white-coat hypertension), particularly if there is no diabetes, OD, CVD or CKD, have lower risk than sustained hypertension for the same office BP. BP, blood pressure; CV, cardiovascular; DBP, diastolic blood pressure; HT, hypertension; SBP, systolic blood pressure.
Laboratory investigations
Laboratory investigations are directed at providing evidence for additional risk factors, searching for secondary hypertension and looking for organ damage. Investigations should proceed from the most simple to the more complicated ones, as summarized in Table 9 .
Searching for asymptomatic organ damage
Owing to the importance of asymptomatic organ damage as an intermediate stage in the continuum of cardiovascular disease, and as a determinant of overall cardiovascular disease, signs of organ involvement should be sought carefully by appropriate techniques as indicated below. To allow the patients to sit for 3-5 min before beginning BP measurements. To take at least two BP measurements, in the sitting position, spaced 1-2 min apart, and additional measurements if the first two are quite different. Consider the average BP if deemed appropriate. To take repeated measurements of BP to improve accuracy in patients with arrhythmias, such as atrial fibrillation. To use a standard bladder (12-13 cm wide and 35 cm long), but have a larger and a smaller bladder available for large (arm circumference >32 cm) and thin arms, respectively. To have the cuff at the heart level, whatever the position of the patient. When adopting the auscultatory method, use phase I and V (disappearance) Korotkoff sounds to identify SBP and DBP, respectively. To measure BP in both arms at first visit to detect possible differences. In this instance, take the arm with the higher value as the reference. To measure at first visit BP 1 and 3 min after assumption of the standing position In elderly participants, diabetic patients and in other conditions in which orthostatic hypotension may be frequent or suspected. To measure, in case of conventional BP measurement, heart rate by pulse palpation (at least 30 s) after the second measurement in the sitting position.
BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
Heart
An ECG is recommended in all hypertensive patients to detect LVH, left atrial dilatation, arrhythmias, or concomitant heart disease.
I B
In all patients with a history or physical examination suggestive of major arrhythmias, long-term ECG monitoring, and, in case of suspected exercise-induced arrhythmias, a stress ECG test should be considered.
IIa C An echocardiogram should be considered to refine CV risk, and confirm ECG diagnosis of LVH, left atrial dilatation or suspected concomitant heart disease, when these are suspected.
IIa B
Whenever history suggests myocardial ischaemia, a stress ECG test is recommended, and, if positive or ambiguous, an imaging stress test (stress echocardiography, stress cardiac magnetic resonance or nuclear scintigraphy) is recommended.
I C Arteries
Ultrasound scanning of carotid arteries should be considered to detect vascular hypertrophy or asymptomatic atherosclerosis, particularly in the elderly.
IIa B
Carotid-femoral PWV should be considered to detect large artery stiffening.
Ankle-brachial index should be considered to detect PAD.
IIa B Kidney
Measurement of serum creatinine and estimation of GFR is recommended in all hypertensive patients.
I B
Assessment of urinary protein is recommended in all hypertensive patients by dipstick.
Assessment of microalbuminuria is recommended in spot urine and related to urinary creatinine excretion.
I B Fundoscopy
Examination of the retina should be considered in difficult to control or resistant hypertensive patients to detect haemorrhages, exudates, and papilloedema, which are associated with increased CV risk.
IIa C
Examination of the retina is not recommended in mild-to-moderate hypertensive patients without diabetes, except in young patients.
III C Brain
In hypertensive patients with cognitive decline, brain magnetic resonance imaging or computed tomography may be considered for detecting silent brain infarctions, lacunar infarctions, microbleeds, and white matter lesions.
IIb C 
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Searching for secondary forms of hypertension
A specific, potentially reversible cause of BP elevation can be identified in a relatively small number of adult patients with hypertension. However if basal work-up leads to the suspicion of a secondary form of hypertension, the patient should be referred to a specialized centre where specific diagnostic procedures may be performed.
TREATMENT APPROACH
Recommendations of previous guidelines revised
The 2007 Fig. 1 . See 4.3 and 6.5 for evidence that, in patients with diabetes, the optimal DBP target is between 80 and 85 mmHg. In the high normal blood pressure (BP) range, drug treatment should be considered in the presence of a raised out-of-office BP (masked hypertension). See 4.2 and 6.3 for lack of evidence in favour of drug treatment in young individuals with isolated systolic hypertension. CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HT, hypertension; OD, organ damage; RF, risk factor; SBP, systolic blood pressure.
When
to initiate antihypertensive drug treatment 4.3 Blood pressure treatment targets
TREATMENT STRATEGIES
Lifestyle changes
Appropriate lifestyle changes are the cornerstone for the prevention of hypertension. They are also important for its treatment, although they should never delay the initiation of drug therapy in patients at high level of risk. In addition to the BP-lowering effect, lifestyle changes contribute to the control of other cardiovascular risk factors and clinical conditions.
The lifestyle measures that have been shown to be capable of reducing BP and therefore recommended are as follows:
1. salt restriction to 5-6 g/day; 2. moderation of alcohol consumption to no more than 20-30 g of ethanol per day in men and 10-20 g/day in women; 3. high consumption of vegetables and fruits and lowfat dairy products; 4. reduction of weight to a BMI of 25 kg/m 2 and waist circumference to less than 102 cm in men and less than 88 cm in women; 5. at least 30 min of moderate dynamic exercise on 5 to 7 days per week. IIa B e) should be considered in patients with diabetic or non-diabetic CKD.
IIa B
In elderly hypertensives less than 80 years old with SBP ≥160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg.
In fit elderly patients less than 80 years old SBP values <140 mmHg may be considered, whereas in the fragile elderly population SBP goals should be adapted to individual tolerability.
I A IIb C
In individuals older than 80 years and with initial SBP ≥160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg provided they are in good physical and mental conditions.
I B
A DBP target of <90 mmHg is always recommended, except in patients with diabetes, in whom values <85 mmHg are recommended. It should nevertheless be considered that DBP values between 80 and 85 mmHg are safe and well tolerated.
I A
Blood pressure goals in hypertensive patients
CHD, coronary heart disease; CKD, chronic kidney disease; CV, cardiovascular; DBP, diastolic blood pressure; SBP, systolic blood pressure; TIA, transient ischaemic attack.
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Monotherapy and combination therapy
The current guidelines share the 2007 Guidelines' opinion that monotherapy can reduce BP to target only in a limited number of patients and that most patients require the combination of at least two drugs, and they reconfirm that initiation with a drug combination can be considered in patients at high cardiovascular risk or with markedly high BP. The algorithm of Fig. 3 , however, is a modification of the 2007 one, to emphasize that adding drugs to drugs should be done with attention to results and any compound overtly ineffective or minimally effective should be replaced, rather than retained in an automatic step-up multiple-drug approach. Combinations to be preferred or avoided are illustrated in Fig. 4 . Diuretics (thiazides, chlorthalidone and indapamide), beta-blockers, calcium antagonists, ACE inhibitors, and angiotensin receptor blockers are all suitable and recommended for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations with each other.
Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of OD.
Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline BP or at high CV risk. Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. IIa C Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favoured, because reducing the number of daily pills improves adherence, which is low in patients with hypertension.
IIb B
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TREATMENT STRATEGIES IN SPECIAL CONDITIONS
In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal haemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered.
In women with child-bearing potential RAS blockers are not recommended and should be avoided.
Methyldopa, labetolol and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetolol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). 
Treatment strategies in hypertensive women
BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; OD, organ damage; RAS, renin-angiotensin system; SBP, systolic blood pressure.
Recommendations
In elderly hypertensives with SBP ≥160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg.
In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values ≥140 mmHg with a target SBP <140 mmHg if treatment is well tolerated.
In individuals older than 80 years with an initial SBP ≥160 mmHg it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions.
In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment.
Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes octogenarian.
All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. 6.5 Diabetes mellitus 6.6 Metabolic syndrome 6.7 Diabetic and nondiabetic nephropathy
Cerebrovascular disease
Recommendations While initiation of antihypertensive drug treatment in diabetic patients whose SBP is ≥160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is ≥140 mmHg.
A SBP goal <140 mmHg is recommended in patients with diabetes.
The DBP target in patients with diabetes is recommended to be <85 mmHg.
All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria.
It is recommended that individual drug choice takes comorbidities into account.
Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes. 
Recommendations
Lowering SBP to <140 mmHg should be considered.
When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored.
RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria.
Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents.
Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended.
Aldosterone antagonists cannot be recommended in CKD, especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalaemia. 
Therapeutic strategies in hypertensive patients with nephropathy
Recommendations Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset.
As the metabolic syndrome can be considered a 'pre-diabetic' state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent.
It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is ≥140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. 
Recommendations
It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values.
Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or TIA, even when initial SBP is in the 140-159 mmHg range.
In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered.
In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher.
All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. 6.9 Heart disease 6.10 Atherosclerosis, arteriosclerosis and peripheral artery disease
In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered.
In hypertensive patients with a recent myocardial infarction beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred, for symptomatic reasons (angina).
Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe LV dysfunction to reduce mortality and hospitalization.
In patients with heart failure and preserved EF, there is no evidence that antihypertensive therapy per se or any particular drug, is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered.
ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation.
It is recommended that all patients with LVH receive antihypertensive agents.
In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers and calcium antagonists. Therapeutic strategies in hypertensive patients with heart disease ACE, angiotensin-converting enzyme; CHD, coronary heart disease; EF, ejection fraction; LV, left ventricular; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers.
In hypertensive patients with a PWV above 10 m/s all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved.
Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. When overt CHD is present, it is recommended to administer statin therapy to achieve low-density lipoprotein cholesterol levels <1.8 mmol/l (70 mg/dl).
Antiplatelet therapy, in particular low-dose aspirin, is recommended in hypertensive patients with previous CV events.
Aspirin should also be considered in hypertensive patients with reduced renal function or a high CV risk, provided that BP is well controlled.
Aspirin is not recommended for CV prevention in low-moderate risk hypertensive patients, in whom absolute benefit and harm are equivalent.
In hypertensive patients with diabetes, a HbA 1c target of <7.0% is recommended with antidiabetic treatment.
In more fragile elderly patients with a longer diabetes duration, more comorbidities and at high risk, treatment to a HbA 1c target of <7.5-8.0% should be considered. 
Treatment of risk factors associated with hypertension
BP, blood pressure; CHD, coronary heart disease; CV, cardiovascular.
Recommendations
In resistant hypertensive patients it is recommended that physicians check whether the drugs included in the existing multiple drug regimen have any BP lowering effect, and withdraw them if their effect is absent or minimal.
Mineralocorticoid receptor antagonists, amiloride, and the alpha-1-blocker doxazosin should be considered, if no contraindication exists.
In case of ineffectiveness of drug treatment invasive procedures such as renal denervation and baroreceptor stimulation may be considered.
Until more evidence is available on the long-term efficacy and safety of renal denervation and baroreceptor stimulation, it is recommended that these procedures remain in the hands of experienced operators and diagnosis and follow-up restricted to hypertension centers.
It is recommended that the invasive approaches are considered only for truly resistant hypertensive patients, with clinic values ≥160 mmHg SBP or ≥110 mmHg DBP and with BP elevation confirmed by ABPM. 
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FOLLOW-UP
Follow-up visits
After initiation of antihypertensive drug therapy, it is important to see the patient at 2-week to 4-week intervals to evaluate the effects on BP and to assess possible sideeffects. Some medications will have an effect within days or weeks but a continued delayed response may occur during the first 2 months. Once the target is reached, a visit interval of a few months is reasonable.
Elevated blood pressure at control visits
Patients and physicians have a tendency to interpret an uncontrolled BP at a given visit as due to occasional factors and thus to downplay its clinical significance. Due attention should be given to poor adherence or irregular consumption of drugs (sometimes because of adverse effects), to the white-coat effect and to substances or drugs opposing the antihypertensive effect of treatment.
Can antihypertensive medication be stopped?
In some patients, in whom treatment is accompanied by an effective BP control for an extended period, it may be possible to reduce the number and dosage of drugs. This may be particularly the case if BP control is accompanied by healthy lifestyle changes. Reduction of medications should be made gradually and the patient should frequently be checked because of the risk of reappearance of hypertension.
IMPROVEMENT OF BLOOD PRESSURE CONTROL IN HYPERTENSION
Despite overwhelming evidence that hypertension is a major cardiovascular risk factor and that BP-lowering substantially reduce the risk, there is evidence that all over the world a noticeable proportion of hypertensive individuals are unaware of this condition or, if aware, do not undergo treatment; target BP values are seldom achieved; failure to achieve BP control is associated with persistence of an elevated cardiovascular risk; and the rate of awareness of hypertension and BP control is improving slowly or not at all. As a consequence, high BP remains a leading cause of death and cardiovascular morbidity in Europe, as elsewhere in the world. Overall, three main causes of the low rate of BP control in real life have been identified: physician inertia; patient low adherence to treatment; and deficiencies of healthcare systems in their approach to chronic diseases. Methods to improve adherence to physicians' recommendations are listed in Table 12 . Intensified care (monitoring, telephone follow-up, reminders, home visits, telemonitoring of home blood pressure, social support, computeraided counselling and packaging) Interventions directly involving pharmacists Reimbursement strategies to improve general practitioners' involvement in evaluation and treatment of hypertension BP, blood pressure. a Almost all of the interventions that were effective for long-term care were complex, including combinations of more convenient care, information, reminders, self-monitoring, reinforcement, counselling, family therapy, psychological therapy, crisis intervention, manual telephone follow-up, supportive care, worksite and pharmacy-based programmes.
